NewAmsterdam Pharma Company N.V. Investment Income, Interest
NewAmsterdam Pharma Company N.V. (NAMS) reported Investment Income, Interest of $5.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. investment income, interest for the quarter ending 2026-06-30 was $5.81M, a 17.65% decline year-over-year.
- NewAmsterdam Pharma Company N.V. investment income, interest for the quarter ending 2026-03-31 was $5.65M, a 23.14% decline year-over-year.
- NewAmsterdam Pharma Company N.V. investment income, interest for the quarter ending 2025-12-31 was $6.47M, a 44.33% increase year-over-year.
- NewAmsterdam Pharma Company N.V. investment income, interest for the quarter ending 2025-09-30 was $6.71M, a 51.09% increase year-over-year.
- NewAmsterdam Pharma Company N.V. investment income, interest for fiscal 2025 was $27.59M, a 63.45% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. investment income, interest for fiscal 2024 was $16.88M, a 49.61% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. investment income, interest for fiscal 2023 was $11.28M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.81M 10-Q · filed 2026-08-05 | $11.46M 10-Q · filed 2026-08-05 | $17.93M derived: sum of 3 quarters · filed 2026-08-05 | $24.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.65M 10-Q · filed 2026-05-07 | $12.12M derived: sum of 2 quarters · filed 2026-05-07 | $18.84M derived: sum of 3 quarters · filed 2026-05-07 | $25.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $13.19M derived: sum of 2 quarters · filed 2026-02-18 | $20.24M derived: sum of 3 quarters · filed 2026-08-05 | $27.59M 10-K · filed 2026-02-18 |
| 2025-09-30 | $6.71M 10-Q · filed 2025-11-05 | $13.77M derived: sum of 2 quarters · filed 2026-08-05 | $21.12M 10-Q · filed 2025-11-05 | $25.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.05M 10-Q · filed 2026-08-05 | $14.41M 10-Q · filed 2026-08-05 | $18.89M derived: sum of 3 quarters · filed 2026-08-05 | $23.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $7.35M 10-Q · filed 2026-05-07 | $11.84M derived: sum of 2 quarters · filed 2026-05-07 | $16.28M derived: sum of 3 quarters · filed 2026-05-07 | $21.15M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $8.93M derived: sum of 2 quarters · filed 2026-02-18 | $13.80M derived: sum of 3 quarters · filed 2026-02-18 | $16.88M 10-K · filed 2026-02-18 |
| 2024-09-30 | $4.44M 10-Q · filed 2025-11-05 | $9.31M derived: sum of 2 quarters · filed 2025-11-05 | $12.40M 10-Q · filed 2025-11-05 | $15.06M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $4.87M 10-Q · filed 2025-08-06 | $7.95M 10-Q · filed 2025-08-06 | $10.62M derived: sum of 3 quarters · filed 2026-02-18 | $13.68M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | $3.08M 10-Q · filed 2025-05-08 | $5.75M derived: sum of 2 quarters · filed 2026-02-18 | $8.81M derived: sum of 3 quarters · filed 2026-02-18 | $13.42M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $5.73M derived: sum of 2 quarters · filed 2026-02-18 | $10.34M derived: sum of 3 quarters · filed 2026-02-18 | $11.28M 10-K · filed 2026-02-18 |
| 2023-09-30 | $3.06M 10-Q · filed 2024-11-06 | $7.67M derived: sum of 2 quarters · filed 2024-11-06 | $8.62M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $4.61M 10-Q · filed 2024-08-07 | $5.56M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $943.00K 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |